Close Menu

NEW YORK (GenomeWeb) –Bristol-Myers Squibb plans to use Natera's circulating tumor DNA assay, Signatera, to determine whether it can successfully identify non-small cell cancer patients who might benefit from BMS's Opdivo (nivolumab) immunotherapy, Natera announced today.

Patients enrolled in the study will first undergo surgical resection of their tumor. The Signatera assay will be used to select patients with minimal residual disease to receive standard of care adjuvant therapy or adjuvant therapy plus Opdivo.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.